Advertising, labelling and packaging requirements for biologics in USA MCQs With Answer

Introduction
This quiz collection addresses advertising, labelling, and packaging requirements for biologics in the USA, tailored for M.Pharm students studying Regulatory Aspects of Herbal and Biologicals (MRA202T). It summarizes key FDA expectations for biologic product labels, packaging integrity, cold-chain handling, and promotional communications. Questions cover statutory and guidance-based topics such as Biologics License Application (BLA) labeling, biosimilar naming, Prescription Drug advertising rules, REMS, barcoding, lot/expiration requirements, patient information, and restrictions on off‑label promotion. Use these MCQs to test and deepen your practical understanding of regulatory controls that ensure safe, effective, and truthful presentation of biologic medicines to healthcare professionals and patients.

Q1. Which FDA regulation specifically requires that prescription drug products, including many biologics, bear a machine-readable barcode on the immediate container label?

• 21 CFR 201.25
• 21 CFR 610.9
• 21 CFR 201.56
• 21 CFR 314.50

Correct Answer: 21 CFR 201.25

Q2. Under FDA guidance, what is the principal legal standard for promotional advertising of biologics?

• Truthful, non-misleading, and based on substantial evidence
• Maximizing market share regardless of evidence
• Focusing only on benefits without mentioning risks
• Targeting only prescribers with selective data

Correct Answer: Truthful, non-misleading, and based on substantial evidence

Q3. Which document must be included in physician-targeted promotional materials as the authoritative source of safety and efficacy information?

• Full Prescribing Information (FPI) or “Prescribing Information”
• Patient Medication Guide only
• Company press release
• Social media posts

Correct Answer: Full Prescribing Information (FPI) or “Prescribing Information”

Q4. For biologics, the FDA’s naming policy for nonproprietary names of biologic products typically requires:

• A core nonproprietary name plus a unique, meaningless four-letter suffix for biologics licensed separately
• No suffix; all biologics share the same INN
• Only brand names may differ, not nonproprietary names
• Use of country-specific trade names as nonproprietary names

Correct Answer: A core nonproprietary name plus a unique, meaningless four-letter suffix for biologics licensed separately

Q5. Which FDA requirement addresses content and format for the “Highlights of Prescribing Information” and the structured labeling format for biologics?

• 21 CFR 201.57
• 21 CFR 610.3
• 21 CFR 201.100
• 21 CFR 314.420

Correct Answer: 21 CFR 201.57

Q6. What labeling element is essential on the immediate container of a parenteral biologic to ensure traceability in case of adverse events?

• Lot or batch number and expiration date
• Marketing claim and sales region
• Detailed manufacturing process description
• Distributor telephone number only

Correct Answer: Lot or batch number and expiration date

Q7. Which of the following is a primary FDA concern when biologic products are promoted directly to consumers (DTC advertising)?

• That DTC adverts present a fair balance of benefits and risks and are not misleading
• That adverts only emphasize pricing and discounts
• That adverts avoid any mention of side effects altogether
• That adverts use celebrity endorsements exclusively

Correct Answer: That DTC adverts present a fair balance of benefits and risks and are not misleading

Q8. Which program may be required for certain biologics to ensure safe use when routine labeling is insufficient to mitigate serious risks?

• REMS (Risk Evaluation and Mitigation Strategies)
• PMA (Premarket Approval)
• ANDA (Abbreviated New Drug Application)
• LLP (Limited Labeling Program)

Correct Answer: REMS (Risk Evaluation and Mitigation Strategies)

Q9. Under the Biologics Price Competition and Innovation Act (BPCIA), which resource lists FDA‑licensed biological products and whether they are biosimilars or interchangeable?

• The Purple Book
• The Orange Book
• The Green Book
• The Blue Book

Correct Answer: The Purple Book

Q10. What labeling statement replaced the old pregnancy letter categories and must be used in biologic prescribing information to communicate pregnancy and lactation information?

• Pregnancy and Lactation Labeling Final Rule (PLLR) narrative sections
• Pregnancy Category A/B/C/D/X letters only
• Short bullet stating “Use at physician discretion”
• No mention of pregnancy information is allowed

Correct Answer: Pregnancy and Lactation Labeling Final Rule (PLLR) narrative sections

Q11. Which practice is explicitly prohibited for companies marketing biologics under FDA regulations governing promotional labeling?

• Promotion of unapproved (off‑label) uses as safe and effective
• Distribution of peer-reviewed journal reprints when properly contextualized
• Providing quantitative benefit information consistent with the label
• Making a fair‑balance presentation of risks and benefits

Correct Answer: Promotion of unapproved (off‑label) uses as safe and effective

Q12. Which packaging requirement is most critical for many biologics that are sensitive to temperature excursions?

• Validated cold‑chain packaging and temperature excursion controls
• Inclusion of promotional inserts only
• Use of opaque packaging regardless of storage conditions
• Single‑use decorative outer box

Correct Answer: Validated cold‑chain packaging and temperature excursion controls

Q13. When a biosimilar is approved, its labeling compared to the reference product must:

• Accurately reflect approved indications and may differ if not approved for certain indications
• Always mirror the reference product label word‑for‑word
• List only the reference product’s clinical trials without biosimilar data
• Exclude any safety warnings to simplify label length

Correct Answer: Accurately reflect approved indications and may differ if not approved for certain indications

Q14. Which of the following is required to be prominent in physician labeling and advertising to ensure clinicians are aware of serious risks associated with a biologic?

• Boxed warning (Black Box)
• Company mission statement
• Sales performance data
• Comparative pricing information

Correct Answer: Boxed warning (Black Box)

Q15. Which law strengthens track-and-trace requirements across the pharmaceutical supply chain and affects biologic packaging and transaction documentation?

• Drug Supply Chain Security Act (DSCSA)
• Food Additives Amendment
• Hatch-Waxman Act
• Medical Device Amendments

Correct Answer: Drug Supply Chain Security Act (DSCSA)

Q16. In addition to contents and dosing, what labeling element is essential for injectable biologics to guide healthcare professionals during administration?

• Route of administration and reconstitution or dilution instructions
• Full manufacturing batch record
• Competitors’ dosing recommendations
• Company’s market share data

Correct Answer: Route of administration and reconstitution or dilution instructions

Q17. For patient-facing materials accompanying biologics, the FDA expects information to be:

• Clear, accurate, and useful for safe use (e.g., Patient Counseling Information, Medication Guides when required)
• Highly technical and identical to investigator brochures
• Exclusively promotional and benefit-focused
• Omitted to reduce printing costs

Correct Answer: Clear, accurate, and useful for safe use (e.g., Patient Counseling Information, Medication Guides when required)

Q18. Which element is NOT normally required on the immediate label of a licensed biologic product?

• Detailed step‑by‑step manufacturing process
• Manufacturer name and address
• Established (nonproprietary) name with strength
• Lot number and expiration date

Correct Answer: Detailed step‑by‑step manufacturing process

Q19. When using social media for biologic promotion, a firm must ensure:

• That brief communications are not misleading and that adequate provision directs users to full prescribing information
• That every post contains the entire Prescribing Information text
• That adverse events are never reported or referenced
• That only influencers without medical expertise are used to promote the product

Correct Answer: That brief communications are not misleading and that adequate provision directs users to full prescribing information

Q20. Which statutory definition distinguishes “biological products” and is the basis for regulatory requirements such as BLAs and biologics labeling?

• The definition in the Public Health Service Act (PHS Act) as biologics derived from living organisms or their products
• The Hatch-Waxman definition for small molecules only
• The definition in the Federal Food, Drug, and Cosmetic Act limited to devices
• A definition that classifies biologics strictly as herbal supplements

Correct Answer: The definition in the Public Health Service Act (PHS Act) as biologics derived from living organisms or their products

Download